Practical recommendations for the management of diabetes in patients with COVID-19

Lancet Diabetes Endocrinol. 2020 Jun;8(6):546-550. doi: 10.1016/S2213-8587(20)30152-2. Epub 2020 Apr 23.

Abstract

Diabetes is one of the most important comorbidities linked to the severity of all three known human pathogenic coronavirus infections, including severe acute respiratory syndrome coronavirus 2. Patients with diabetes have an increased risk of severe complications including Adult Respiratory Distress Syndrome and multi-organ failure. Depending on the global region, 20-50% of patients in the coronavirus disease 2019 (COVID-19) pandemic had diabetes. Given the importance of the link between COVID-19 and diabetes, we have formed an international panel of experts in the field of diabetes and endocrinology to provide some guidance and practical recommendations for the management of diabetes during the pandemic. We aim to briefly provide insight into potential mechanistic links between the novel coronavirus infection and diabetes, present practical management recommendations, and elaborate on the differential needs of several patient groups.

Publication types

  • Review

MeSH terms

  • Betacoronavirus / pathogenicity*
  • COVID-19
  • Comorbidity
  • Contraindications, Drug
  • Coronavirus Infections / physiopathology*
  • Coronavirus Infections / therapy
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / physiopathology
  • Diabetes Mellitus, Type 2 / drug therapy*
  • Diabetes Mellitus, Type 2 / physiopathology
  • Humans
  • Hypoglycemic Agents / administration & dosage
  • Hypoglycemic Agents / adverse effects*
  • Multiple Organ Failure / chemically induced
  • Multiple Organ Failure / physiopathology
  • Pandemics*
  • Pneumonia, Viral / physiopathology*
  • Pneumonia, Viral / therapy
  • Practice Guidelines as Topic
  • Respiratory Distress Syndrome / chemically induced
  • Respiratory Distress Syndrome / physiopathology
  • SARS-CoV-2

Substances

  • Hypoglycemic Agents